Smartlab Europe

Takeda’s Donation to Aid Earthquake Relief Efforts in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...
- Advertisement -

Takeda Pharmaceutical Company Limited announced 300 million Japanese yen donation to aid emergency relief for the earthquake on March 11, through The Japanese Red Cross Society, in view of the huge damages in the wide geographical area affected in prefectures such as Iwate, Miyagi, Fukushima and others. In addition to the cash donation aforementioned, Takeda is planning the donation of pharmaceutical products (both ethical and over-the-counter) and all other supports that are feasible for the Company.

We would like to express heartfelt condolences to the families of the victims, and we also sincerely wish the safety of the people affected by this earthquake and the earliest possible recovery of the relevant region.

Latest stories

Related stories

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »